All In Biotech

Free tool

FAERS Monitor: Xcopri

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 212839 or its brand name (Xcopri, Cenobamate). Reports on generic versions are filed under their own applications.

Reports

8,531

Serious

3,375

40% of reports

Hospitalization

1,798

Death reported

208

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • seizure2,543
  • product dose omission issue1,880
  • fatigue845
  • somnolence823
  • off label use691
  • dizziness668
  • product use issue608
  • fall470
  • headache391
  • wrong technique in product usage process382
  • drug ineffective380
  • drug interaction364
  • feeling abnormal302
  • gait disturbance289
  • balance disorder263

Reports by year received

View as table
YearReports
20195
202084
20211,679
2022612
2023558
20241,527
20252,057
20262,009

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,628 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
seizureSignal2,54355.553.7133,730
product dose omission issueSignal1,88015.915.226,356
somnolenceSignal82310.19.56,788
product use issueSignal6088.07.43,738
balance disorderSignal2637.56.71,482
drug interactionSignal3645.75.11,402
wrong technique in product usage processSignal3824.74.21,101
gait disturbanceSignal2893.73.3578
fallSignal4703.53.2843
dizzinessSignal6683.33.11,096
feeling abnormalSignal3023.12.8435
fatigueSignal8452.72.5920
off label use6911.91.8331
headache3911.51.475
drug ineffective3800.70.647

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.